Skip to main content

HubXchange

HubXChange logo

Antibody Therapeutics Xchange - San Francisco - 2024

Page Banner 1

Loading
Search Filters
  • Stream
  • Industry Expert
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
08:00
  1. Registration
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
08:30
  1. Opening Address & Keynote Presentation
    Opening Address & Keynote Presentation
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
09:05
  1. Target Selection
    Technologies to identify targets with optimal therapeutic windows.
    60 mins
    • Target Selection
     
    Remi-Martin Laberge
    Remi-Martin Laberge, Co-founder, SVP and Head of Research - Arda Therapeutics
  2. Lead Identification & Optimization
    Novel approaches in antibody lead identification & optimization
    60 mins
    • Lead Identification & Optimization
    Amir Porat
    Amir Porat, Associate Director, Protein Sciences - Prothena Corporation
  3. Bi/Multispecifics
    Bi/tri-specific strategies for overcoming cell engager toxicity
    60 mins
    • Bi/Multispecifics
     
    Lu Shan
    Lu Shan, Senior Director, Antibody Discovery and Protein Engineering - Alector
  4. Emerging Technologies
    What is the optimum human CDR-H3 repertoire for antibody discovery? (TOPIC TBC)
    60 mins
    • Emerging Technologies
    Arnima Bisht
    Arnima Bisht, Senior Director - Oxford BioTherapeutics
  5. Formats & Scaffolds
    Challenges of using single domain antibodies as new modalities of multifunctional biologics
    60 mins
    • Formats & Scaffolds
    Starlynn Clarke
    Starlynn Clarke, Director, Preclinical Biology - Rondo Therapeutics
10:10
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
10:40
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
11:10
  1. Morning Refreshments
    10 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
11:20
  1. Target Selection
    Sponsor Led Roundtable Discussion (Topic TBC)
    Sponsor Led Roundtable Discussion (Topic TBC)
    60 mins
    • Target Selection
    ImmunXperts
  2. Lead Identification & Optimization
    Sponsor Led Roundtable Discussion (Topic TBC)
    Sponsor Led Roundtable Discussion (Topic TBC)
    60 mins
    • Lead Identification & Optimization
    Bio-Rad
  3. Formats & Scaffolds
    Sponsor Led Roundtable Discussion (Topic TBC)
    Sponsor Led Roundtable Discussion (Topic TBC)
    60 mins
    • Formats & Scaffolds
    WuXi Biologics
  4. Emerging Technologies
    TOPIC TBC by Alivamab
    TOPIC TBC by Alivamab
    60 mins
    • Emerging Technologies
    Jane Seagal
    Jane Seagal, Vice President, Antibody Discovery - Ablexis and AlivaMab Biologics
12:20
  1. Networking Lunch
    60 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
13:20
  1. Spotlight Presentation: Engineering Unique Properties in Next-Gen Antibody Therapies
    Spotlight Presentation: Engineering Unique Properties in Next-Gen Antibody Therapies
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
    Jordon Wang
    Jordon Wang, Chief Operating Officer - Avantgen
13:55
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
14:25
  1. 1-2-1 Meetings / Networking Break
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
15:00
  1. Spotlight Presentation
    Spotlight Presentation
    30 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
15:35
  1. Emerging Technologies
    Poster Presentation: Cutting through the hype: Real-world applications of AI in antibody discovery and engineering
    Poster Presentation: Cutting through the hype: Real-world applications of AI in antibody discovery and engineering
    30 mins
    • Emerging Technologies
    Barry Duplantis
    Barry Duplantis, Director of Global Business Development - Ailux Biologics (XtalPi)
  2. Target Selection
    Poster Presentation: Strategies to amplify the therapeutic potential of rabbit-derived antibodies
    Poster Presentation: Strategies to amplify the therapeutic potential of rabbit-derived antibodies
    30 mins
    • Target Selection
    Andra Li
    Andra Li, Scientific Director - ImmunoPrecise Antibodies Canada Ltd.
  3. Lead Identification & Optimization
    Poster Presentation (TOPIC TBC)
    Poster Presentation (TOPIC TBC)
    30 mins
    • Lead Identification & Optimization
  4. Formats & Scaffolds
    Poster Presentation (TOPIC TBC)
    Poster Presentation (TOPIC TBC)
    30 mins
    • Formats & Scaffolds
16:05
  1. Target Selection
    Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer
    60 mins
    • Target Selection
     
    Steven Everett
    Steven Everett, Founder & CEO - MaveriX Oncology, Inc.
  2. Formats & Scaffolds
    Current challenges in design of bispecific/ chimeric antigen receptors for solid tumours
    60 mins
    • Formats & Scaffolds
    Alexander Martinko
    Alexander Martinko, Director of Antibody Engineering - Cartography Biosciences
  3. Bi/Multispecifics
    Developing therapies to target multiple immune pathways (Topic TBC)
    60 mins
    • Bi/Multispecifics
    Narayan Sastri Palla
    Narayan Sastri Palla, Principal Scientist - TrueBinding
  4. Emerging Technologies
    What is the optimum human CDR-H3 repertoire for antibody discovery? (Topic TBC)
    60 mins
    • Emerging Technologies
    Arnima Bisht
    Arnima Bisht, Senior Director - Oxford BioTherapeutics
17:05
  1. Evening Drinks Reception
    60 mins
    • Target Selection
    • Lead Identification & Optimization
    • Formats & Scaffolds
    • Bi/Multispecifics
    • Emerging Technologies
Search